- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03442751
Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
January 29, 2024 updated by: Glaukos Corporation
A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus
To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus.
Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.
Study Overview
Status
Completed
Conditions
Detailed Description
Up to 275 study eyes with progressive keratoconus will be enrolled.
Study eyes will be randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary efficacy endpoint is a difference of ≥ 1 diopter between treatment groups in the mean change in Kmax from baseline to Month 6.
Study Type
Interventional
Enrollment (Actual)
201
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Ophthalmic Consultants of Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 53 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Be between 12 and 55 years of age, male or female, of any race;
- Provide written informed consent and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well as having a parent or legal guardian sign an informed consent
- Ability to read English or Spanish to complete the NEI-VFQ 25 questionnaire;
- Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
- For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of each study eye; must not be lactating, and must agree to use a medically acceptable form of birth control for at least one week prior to the randomization visit, and continue to use the method for one month following the treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
- Having topographic and clinical evidence of keratoconus
Exclusion Criteria:
- Contraindications, sensitivity or known allergy to the use of the test article(s) or their components;
- If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
- Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications.
- A history of delayed epithelial healing in the eye to be treated or a current condition that may interfere with or prolong epithelial healing;
- A history of previous corneal cross-linking treatment in the eye to be treated;
- Have used an investigational drug or device within 30 days of screening or be concurrently enrolled in another investigational drug or device trial within 30 days of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Epithelium-on CXL Treatment Group
Study eye receives Test Article A, Test Article B, and exposed to cross-linking dose of UVA light generated by the KXL medical device system
|
Riboflavin Ophthalmic Solution A
Riboflavin Ophthalmic Solution B
Mock UVA light source
Cross-linking UVA light source
|
Sham Comparator: Sham Treatment/Control Group
Sham eye receives Placebo and and exposed to mock dose of UVA light generated by the KXL medical device system
|
Mock UVA light source
Cross-linking UVA light source
Placebo Vehicle of Test Article
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax
Time Frame: 6 months
|
Mean difference of at least 1 diopter in Kmax change from baseline to Month 6 between treatment groups
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax
Time Frame: 12 months
|
Difference between the CXL and Sham/Control treatment groups in the change from baseline to Month 12 in Kmax
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Valerie Smith, Glaukos Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 6, 2018
Primary Completion (Actual)
November 1, 2019
Study Completion (Actual)
August 10, 2020
Study Registration Dates
First Submitted
February 16, 2018
First Submitted That Met QC Criteria
February 16, 2018
First Posted (Actual)
February 22, 2018
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACP-KXL-308
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progressive Keratoconus
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
University Hospital, ToulouseCentre de Référence National du Kératocône; Sooft ItaliaTerminated
-
Sun Yat-sen UniversityUnknownProgressive KeratoconusChina
-
Democritus University of ThraceCompleted
-
Peschke Meditrade, GmbHUnknown
-
Glaukos CorporationRecruitingProgressive KeratoconusUnited States
-
Region SkaneActive, not recruiting
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Kasr El Aini HospitalCompletedProgressive KeratoconusEgypt
Clinical Trials on Test Article A
-
Omeza, LLCCompletedErythema | SensitisationUnited States
-
University of PittsburghUniversity of Washington; University of North Carolina, Chapel HillCompleted
-
Vyne Therapeutics Inc.Completed
-
Pure GreenUnknownPain | Osteoarthritis, KneeUnited States
-
Omeza, LLCCompletedErythema | Transepidermal Water LossUnited Kingdom
-
Omeza, LLCCompletedAllergic ReactionUnited States
-
Yale-NUS CollegeRaffles InstitutionUnknownWhatsapp, Article, No PhoneSingapore
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited Kingdom
-
Coopervision, Inc.Completed
-
Coloplast A/SCompleted